» Articles » PMID: 27403444

The Hospitalization Costs of Diabetes and Hypertension Complications in Zimbabwe: Estimations and Correlations

Overview
Journal J Diabetes Res
Publisher Wiley
Specialty Endocrinology
Date 2016 Jul 13
PMID 27403444
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Objective. Treating complications associated with diabetes and hypertension imposes significant costs on health care systems. This study estimated the hospitalization costs for inpatients in a public hospital in Zimbabwe. Methods. The study was retrospective and utilized secondary data from medical records. Total hospitalization costs were estimated using generalized linear models. Results. The median cost and interquartile range (IQR) for patients with diabetes, $994 (385-1553) mean $1319 (95% CI: 981-1657), was higher than patients with hypertension, $759 (494-1147) mean $914 (95% CI: 825-1003). Female patients aged below 65 years with diabetes had the highest estimated mean costs ($1467 (95% CI: 1177-1828)). Wound care had the highest estimated mean cost of all procedures, $2884 (95% CI: 2004-4149) for patients with diabetes and $2239 (95% CI: 1589-3156) for patients with hypertension. Age below 65 years, medical procedures (amputation, wound care, dialysis, and physiotherapy), the presence of two or more comorbidities, and being prescribed two or more drugs were associated with significantly higher hospitalization costs. Conclusion. Our estimated costs could be used to evaluate and improve current inpatient treatment and management of patients with diabetes and hypertension and determine the most cost-effective interventions to prevent complications and comorbidities.

Citing Articles

Magnitude, risk factors and economic impacts of diabetic emergencies in developing countries: A systematic review.

Haile H, Gedif Fenta T PLoS One. 2025; 20(2):e0317653.

PMID: 39903717 PMC: 11793792. DOI: 10.1371/journal.pone.0317653.


Prevalence and risk factors for diabetic foot complications among people living with diabetes in Harare, Zimbabwe: a cross-sectional study.

Kuguyo O, Mukona D, Chikwasha V, Gwanzura L, Chirenda J, Matimba A BMC Public Health. 2024; 24(1):677.

PMID: 38439010 PMC: 10910836. DOI: 10.1186/s12889-023-17610-7.


Catastrophic health expenditure of households with hypertension: a comparative study in China.

Zhai X, Zhou Z, Liu G, Lu J, Zhao Y, Cao D Front Public Health. 2023; 11:1176170.

PMID: 37361148 PMC: 10285052. DOI: 10.3389/fpubh.2023.1176170.


Glycemic control among patients with type 2 diabetes in a low resource setting in Rwanda: a prospective cohort study.

Bahizi S, Mugeni R, Banhart D, Mukankuranga C, Makiriro G, Kirk C Pan Afr Med J. 2023; 43:74.

PMID: 36590994 PMC: 9789783. DOI: 10.11604/pamj.2022.43.74.35639.


A Machine Learning Model to Predict Length of Stay and Mortality among Diabetes and Hypertension Inpatients.

Barsasella D, Bah K, Mishra P, Uddin M, Dhar E, Suryani D Medicina (Kaunas). 2022; 58(11).

PMID: 36363525 PMC: 9694021. DOI: 10.3390/medicina58111568.


References
1.
Adigun A, Ishola D, Akintomide A, Ajayi A . Shifting trends in the pharmacologic treatment of hypertension in a Nigerian tertiary hospital: a real-world evaluation of the efficacy, safety, rationality and pharmaco-economics of old and newer antihypertensive drugs. J Hum Hypertens. 2003; 17(4):277-85. DOI: 10.1038/sj.jhh.1001538. View

2.
Makani J, Matuja W, Liyombo E, Snow R, Marsh K, Warrell D . Admission diagnosis of cerebral malaria in adults in an endemic area of Tanzania: implications and clinical description. QJM. 2003; 96(5):355-62. PMC: 5612393. DOI: 10.1093/qjmed/hcg059. View

3.
Mbanya J, Sobngwi E . Diabetes in Africa. Diabetes microvascular and macrovascular disease in Africa. J Cardiovasc Risk. 2003; 10(2):97-102. DOI: 10.1097/01.hjr.0000060842.48106.78. View

4.
Manning W, Mullahy J . Estimating log models: to transform or not to transform?. J Health Econ. 2001; 20(4):461-94. DOI: 10.1016/s0167-6296(01)00086-8. View

5.
Williams R, Van Gaal L, Lucioni C . Assessing the impact of complications on the costs of Type II diabetes. Diabetologia. 2016; 45(Suppl 1):S13-S17. DOI: 10.1007/s00125-002-0859-9. View